
Vikram Thermo India (VIKRAMTH) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
271.1M
Gross Profit
157.4M
58.07%
Operating Income
66.0M
24.33%
Net Income
40.7M
15.03%
Balance Sheet Metrics
Total Assets
1.5B
Total Liabilities
244.4M
Shareholders Equity
1.2B
Debt to Equity
0.20
Cash Flow Metrics
Revenue & Profitability Trend
Vikram Thermo India Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 1.3B | 1.2B | 1.1B | 915.3M | 725.3M |
Cost of Goods Sold | 512.1M | 643.2M | 613.0M | 609.6M | 387.8M |
Gross Profit | 750.2M | 606.3M | 490.7M | 305.7M | 337.4M |
Gross Margin % | 59.4% | 48.5% | 44.5% | 33.4% | 46.5% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 45.6M | 47.4M | 29.1M | 31.2M |
Other Operating Expenses | 188.9M | 77.0M | 61.6M | 47.1M | 55.0M |
Total Operating Expenses | 188.9M | 122.6M | 109.0M | 76.3M | 86.2M |
Operating Income | 421.7M | 342.4M | 236.1M | 119.3M | 161.1M |
Operating Margin % | 33.4% | 27.4% | 21.4% | 13.0% | 22.2% |
Non-Operating Items | |||||
Interest Income | - | 1.4M | 1.4M | 1.3M | 1.4M |
Interest Expense | 9.4M | 10.2M | 10.8M | 7.6M | 4.4M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 187.9M | 340.6M | 230.4M | 117.7M | 159.9M |
Income Tax | 103.8M | 86.8M | 61.2M | 30.8M | 39.2M |
Effective Tax Rate % | 55.2% | 25.5% | 26.6% | 26.1% | 24.5% |
Net Income | 81.0M | 253.8M | 169.1M | 86.9M | 120.7M |
Net Margin % | 6.4% | 20.3% | 15.3% | 9.5% | 16.6% |
Key Metrics | |||||
EBITDA | 477.0M | 375.7M | 271.4M | 146.8M | 183.1M |
EPS (Basic) | - | ₹8.09 | ₹5.39 | ₹2.77 | ₹3.85 |
EPS (Diluted) | - | ₹8.09 | ₹5.39 | ₹2.77 | ₹3.85 |
Basic Shares Outstanding | - | 31357850 | 31357850 | 31357850 | 31357850 |
Diluted Shares Outstanding | - | 31357850 | 31357850 | 31357850 | 31357850 |
Income Statement Trend
Vikram Thermo India Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 1.6M | 28.8M | 33.0M | 13.8M | 1.5M |
Short-term Investments | 9.9M | 149.6M | 112.0M | 107.2M | 102.7M |
Accounts Receivable | 442.4M | 393.1M | 333.5M | 236.5M | 199.3M |
Inventory | 106.4M | 146.6M | 99.3M | 116.4M | 90.8M |
Other Current Assets | 58.1M | -1.0K | 19.4M | 2.0K | 15.3M |
Total Current Assets | 627.6M | 749.1M | 604.4M | 490.6M | 413.1M |
Non-Current Assets | |||||
Property, Plant & Equipment | 449.2M | 21.7M | 18.4M | 17.1M | 16.4M |
Goodwill | 172.0K | 54.0K | 161.0K | 409.0K | 850.0K |
Intangible Assets | - | 54.0K | 161.0K | 409.0K | 850.0K |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 378.0M | -1.0K | -2.0K | 1.0K | -1.0K |
Total Non-Current Assets | 831.3M | 677.7M | 667.7M | 553.0M | 510.2M |
Total Assets | 1.5B | 1.4B | 1.3B | 1.0B | 923.3M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 103.7M | 127.4M | 107.1M | 97.1M | 88.9M |
Short-term Debt | 42.1M | 23.3M | 114.7M | 60.7M | 38.3M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 21.4M | 1.0K | 1.0K | -1.0K | 1.8M |
Total Current Liabilities | 200.7M | 209.8M | 272.2M | 194.2M | 181.2M |
Non-Current Liabilities | |||||
Long-term Debt | 21.9M | 47.1M | 70.4M | 88.4M | 66.0M |
Deferred Tax Liabilities | 21.8M | 34.6M | 32.6M | 26.2M | 19.2M |
Other Non-Current Liabilities | - | - | - | 1.0K | - |
Total Non-Current Liabilities | 43.7M | 81.7M | 103.0M | 114.6M | 85.2M |
Total Liabilities | 244.4M | 291.5M | 375.3M | 308.8M | 266.4M |
Equity | |||||
Common Stock | 313.6M | 313.6M | 313.6M | 62.7M | 62.7M |
Retained Earnings | - | 727.0M | 491.5M | 583.3M | 508.5M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 1.2B | 1.1B | 896.8M | 734.7M | 656.9M |
Key Metrics | |||||
Total Debt | 64.0M | 70.4M | 185.1M | 149.1M | 104.3M |
Working Capital | 426.9M | 539.3M | 332.1M | 296.4M | 231.9M |
Balance Sheet Composition
Vikram Thermo India Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 184.8M | 340.6M | 230.4M | 117.7M | 159.9M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -117.7M | -91.6M | -95.5M | -67.5M | -18.2M |
Operating Cash Flow | 324.2M | 258.9M | 145.2M | 57.7M | 145.8M |
Investing Activities | |||||
Capital Expenditures | -395.5M | -66.4M | -127.4M | -66.0M | -105.8M |
Acquisitions | - | - | - | - | - |
Investment Purchases | -419.5M | -61.0M | - | - | -227.0M |
Investment Sales | 578.8M | 32.5M | - | - | 138.1M |
Investing Cash Flow | -236.7M | -95.7M | -127.6M | -65.9M | -195.0M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -23.5M | -15.7M | -9.4M | -9.4M | -9.4M |
Debt Issuance | 0 | 26.0K | 492.0K | 40.5M | 66.5M |
Debt Repayment | -23.3M | -18.5M | -18.1M | -34.2M | -24.3M |
Financing Cash Flow | -30.0M | -130.4M | 26.6M | 35.5M | 36.8M |
Free Cash Flow | -159.9M | 163.7M | 2.9M | -6.8M | 40.9M |
Net Change in Cash | 57.5M | 32.8M | 44.2M | 27.2M | -12.3M |
Cash Flow Trend
Vikram Thermo India Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
54.85
Price to Book
3.81
Price to Sales
3.74
Profitability Ratios
Profit Margin
25.77%
Operating Margin
37.09%
Return on Equity
6.67%
Return on Assets
5.55%
Financial Health
Current Ratio
3.13
Debt to Equity
5.27
Beta
-0.23
Per Share Data
EPS (TTM)
₹2.69
Book Value per Share
₹38.75
Revenue per Share
₹39.39
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
vikramth | 4.6B | 54.85 | 3.81 | 6.67% | 25.77% | 5.27 |
Sun Pharmaceutical | 3.9T | 37.88 | 5.45 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 70.42 | 10.88 | 14.64% | 23.89% | 0.03 |
Sun Pharma Advanced | 45.5B | -13.34 | -21.04 | 157.88% | -53.22% | -1.24 |
Aarti Drugs | 44.4B | 23.59 | 3.25 | 12.28% | 7.80% | 44.92 |
Sequent Scientific | 43.9B | 154.18 | 6.24 | 2.84% | 1.85% | 62.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.